Merck Expands Keytruda Trial Collaboration With Amgen, Unveils Others
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck’s sBLA for Keytruda in lung cancer has been accepted by FDA and granted an Oct. 2 action date, the firm announced. The company also revealed several new research collaborations to study Keytruda in more combination trials at ASCO.
You may also be interested in...
Merck’s Keytruda Opens Door, But Combination Trials Could Unlock Efficacy
FDA’s approval of Merck’s anti-PD-1 drug pembrolizumab in melanoma marks a major milestone for oncology and industry’s immune checkpoint efforts. But with an overall response rate in labeling of 24%, there’s still room for improvement with combinations and use in earlier lines of therapy.
Tesaro’s Niraparib Takes PARP Inhibitor Lead In Ovarian Cancer
Tesaro Inc. announced the launch of a Phase III trial for its PARP inhibitor niraparib in ovarian cancer, while registrational data from three global Phase III studies for anti-emetic rolapitant are due by the end of 2013.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.